Local Injection of Deferoxamine Improves Neovascularization in Ischemic Diabetic Random Flap by Increasing HIF-1α and VEGF Expression

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Jun 26

PMID 24963878

Citations 25

Authors

Chen Wang

Yuanyuan Cai

Yun Zhang

Zhuyou Xiong

Guangzao Li

Lei Cui

Affiliations

Soon will be listed here.

Abstract

Background: Although the systemic administration of deferoxamine (DFO) is protective in experimental models of normal ischemic flap and diabetic wound, its effect on diabetic flap ischemia using a local injection remains unknown.

Objective: To explore the feasibility of local injection of DFO to improve the survival of ischemic random skin flaps in streptozotocin (STZ)-induced diabetic mice.

Methods: Ischemic random skin flaps were made in 125 mice. Animals were divided into the DFO-treated (n = 20), PBS-treated (n = 16) and untreated (n = 16) groups. Surviving area, vessel density, and expression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α (HIF-1α) were evaluated on the seventh day after local injection.

Results: The viability of DFO-treated flap was significantly enhanced, with increased regional blood perfusion and capillary density compared with those in the two control groups. Fluorescence-activated cell sorting (FACS) analysis demonstrated a marked increase in systemic Flk-1+/CD11b- endothelial progenitor cells (EPCs) in DFO-treated mice. Furthermore, the expression of VEGF and HIF-1α was increased not only in diabetic flap tissue, but also in dermal fibroblasts cultured under hyperglycemic and hypoxic conditions.

Conclusions: Local injection of DFO could exert preventive effects against skin flap necrosis in STZ-induced diabetic mice by elevating the expression of HIF-1α and VEGF, increased EPC mobilization, which all contributed to promote ischemic diabetic flap survival.

Citing Articles

Downregulation of microRNA‑221‑3p promotes angiogenesis of lipoprotein(a)‑injured endothelial progenitor cells by targeting silent information regulator 1 to activate the RAF/MEK/ERK signaling pathway.

Zhang X, Wang S, Qin Y, Guo H Mol Med Rep. 2024; 30(6).

PMID: 39364751 PMC: 11462396. DOI: 10.3892/mmr.2024.13347.

Restoring the Angiogenic Capacity of the Human Diabetic Adipose-derived mesenchymal stem cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α.

Tajali R, Eidi A, Tafti H, Pazouki A, Sharifi A Adv Pharm Bull. 2023; 13(2):350-360.

PMID: 37342375 PMC: 10278222. DOI: 10.34172/apb.2023.021.

Edaravone promotes viability of random skin flaps via activating PI3K/Akt/mTOR signalling pathway-mediated enhancement of autophagy.

Bi M, Qin Y, Zhao L, Zhang X Int Wound J. 2023; 20(8):3088-3104.

PMID: 37042039 PMC: 10502271. DOI: 10.1111/iwj.14184.

Hypoxia in Skin Cancer: Molecular Basis and Clinical Implications.

Jeon S, Jeon M, Choi S, Yoo S, Park S, Lee M Int J Mol Sci. 2023; 24(5).

PMID: 36901857 PMC: 10003002. DOI: 10.3390/ijms24054430.

[Regulatory mechanism of deferoxamine on macrophage polarization and wound healing in mice with deep tissue injury].

Shan H, Zhang Z, Wang X, Hou J, Zhang J Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022; 38(8):767-777.

PMID: 36058700 PMC: 11705561. DOI: 10.3760/cma.j.cn501225-20220114-00007.

References

Zhang T, Gong W, Li Z, Yang S, Zhang K, Yin D . Efficacy of hyperbaric oxygen on survival of random pattern skin flap in diabetic rats. Undersea Hyperb Med. 2007; 34(5):335-9. View

Rica Tanaka , Wada M, Kwon S, Masuda H, Carr J, Ito R . The effects of flap ischemia on normal and diabetic progenitor cell function. Plast Reconstr Surg. 2008; 121(6):1929-1942. DOI: 10.1097/PRS.0b013e3181715218. View

Brem H, Tomic-Canic M . Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007; 117(5):1219-22. PMC: 1857239. DOI: 10.1172/JCI32169. View

Gallagher K, Liu Z, Xiao M, Chen H, Goldstein L, Buerk D . Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest. 2007; 117(5):1249-59. PMC: 1857264. DOI: 10.1172/JCI29710. View

Haimovici R, DAmico D, Gragoudas E, Sokol S . The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002; 109(1):164-71. DOI: 10.1016/s0161-6420(01)00947-2. View

Angel M, Narayanan K, Swartz W, Ramasastry S, Kuhns D, Basford R . Deferoxamine increases skin flap survival: additional evidence of free radical involvement in ischaemic flap surgery. Br J Plast Surg. 1986; 39(4):469-72. DOI: 10.1016/0007-1226(86)90115-3. View

Ceradini D, Yao D, Grogan R, Callaghan M, Edelstein D, Brownlee M . Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem. 2008; 283(16):10930-8. PMC: 2447622. DOI: 10.1074/jbc.M707451200. View

Galiano R, Tepper O, Pelo C, Bhatt K, Callaghan M, Bastidas N . Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004; 164(6):1935-47. PMC: 1615774. DOI: 10.1016/S0002-9440(10)63754-6. View

Shweiki D, Itin A, Soffer D, Keshet E . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359(6398):843-5. DOI: 10.1038/359843a0. View

10.

Botusan I, Sunkari V, Savu O, Catrina A, Grunler J, Lindberg S . Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A. 2008; 105(49):19426-31. PMC: 2614777. DOI: 10.1073/pnas.0805230105. View

11.

Weng R, Li Q, Li H, Yang M, Sheng L . Mimic hypoxia improves angiogenesis in ischaemic random flaps. J Plast Reconstr Aesthet Surg. 2010; 63(12):2152-9. DOI: 10.1016/j.bjps.2010.02.001. View

12.

Lu F, Mizuno H, Uysal C, Cai X, Ogawa R, Hyakusoku H . Improved viability of random pattern skin flaps through the use of adipose-derived stem cells. Plast Reconstr Surg. 2008; 121(1):50-58. DOI: 10.1097/01.prs.0000293876.10700.b8. View

13.

Potier E, Ferreira E, Dennler S, Mauviel A, Oudina K, Logeart-Avramoglou D . Desferrioxamine-driven upregulation of angiogenic factor expression by human bone marrow stromal cells. J Tissue Eng Regen Med. 2008; 2(5):272-8. DOI: 10.1002/term.92. View

14.

Emerit J, Beaumont C, Trivin F . Iron metabolism, free radicals, and oxidative injury. Biomed Pharmacother. 2001; 55(6):333-9. DOI: 10.1016/s0753-3322(01)00068-3. View

15.

Stremmel W, Niederau C, Berger M, Kley H, KRUSKEMPER H, Strohmeyer G . Abnormalities in estrogen, androgen, and insulin metabolism in idiopathic hemochromatosis. Ann N Y Acad Sci. 1988; 526:209-23. DOI: 10.1111/j.1749-6632.1988.tb55507.x. View

16.

Weinstein G, Maves M, McCormack M . Deferoxamine decreases necrosis in dorsally based pig skin flaps. Otolaryngol Head Neck Surg. 1989; 101(5):559-61. DOI: 10.1177/019459988910100508. View

17.

Okauchi M, Hua Y, Keep R, Morgenstern L, Schallert T, Xi G . Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. Stroke. 2010; 41(2):375-82. PMC: 2896218. DOI: 10.1161/STROKEAHA.109.569830. View

18.

Epstein S, Kornowski R, Fuchs S, Dvorak H . Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation. 2001; 104(1):115-9. DOI: 10.1161/01.cir.104.1.115. View

19.

Kang L, Chen Q, Wang L, Gao L, Meng K, Chen J . Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol. 2009; 36(10):e47-56. DOI: 10.1111/j.1440-1681.2009.05219.x. View

20.

Vija L, Farge D, Gautier J, Vexiau P, Dumitrache C, Bourgarit A . Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab. 2009; 35(2):85-93. DOI: 10.1016/j.diabet.2008.10.003. View